Literature DB >> 23817717

Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab.

Stefan Zschiedrich, Eric P Prager, E Wolfgang Kuehn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817717     DOI： 10.7326/0003-4819-159-1-201307020-00023

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  10 in total

1.  Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management.

Authors:  Erika De Sousa Amorim; Miquel Blasco; Luis Quintana; Manel Sole; Santiago Rodríguez de Cordoba; Josep Maria Campistol
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

2.  Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome.

Authors:  Martina Gaggl; Christof Aigner; Dorottya Csuka; Ágnes Szilágyi; Zoltán Prohászka; Renate Kain; Natalja Haninger; Maarten Knechtelsdorfer; Raute Sunder-Plassmann; Gere Sunder-Plassmann; Alice Schmidt
Journal:  J Am Soc Nephrol       Date:  2017-12-27       Impact factor: 10.121

Review 3.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

4.  Hemolytic Uremic Syndrome in Pregnancy and Postpartum.

Authors:  Alexandra Bruel; David Kavanagh; Marina Noris; Yahsou Delmas; Edwin K S Wong; Elena Bresin; François Provôt; Vicky Brocklebank; Caterina Mele; Giuseppe Remuzzi; Chantal Loirat; Véronique Frémeaux-Bacchi; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-08       Impact factor: 8.237

5.  Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment.

Authors:  Erol Demir; Halil Yazici; Yasemin Ozluk; Isin Kilicaslan; Aydin Turkmen
Journal:  Case Rep Nephrol Dial       Date:  2016-12-20

Review 6.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

7.  Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Authors:  Gérard Socié; Marie-Pierre Caby-Tosi; Jing L Marantz; Alexander Cole; Camille L Bedrosian; Christoph Gasteyger; Arshad Mujeebuddin; Peter Hillmen; Johan Vande Walle; Hermann Haller
Journal:  Br J Haematol       Date:  2019-02-15       Impact factor: 6.998

Review 8.  Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes.

Authors:  Renaud Prével; Yahsou Delmas; Vivien Guillotin; Didier Gruson; Etienne Rivière
Journal:  J Clin Med       Date:  2022-02-01       Impact factor: 4.241

Review 9.  Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Authors:  Lilian M Pereira Palma; Craig B Langman
Journal:  J Blood Med       Date:  2016-04-12

10.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.